siRNA targeting VEGFA and methods for treatment in vivo
US9150862B2 · kind B2 · utility
0Cited by
5References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 27, 2013 |
| Grant date | Oct 6, 2015 |
| Priority date | — |
| Expiry date | Aug 27, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.